Although stereotactic radiation provides a noninvasive approach to treating acoustic neuromas, it also carries the risk of hearing loss over time for a sizable portion of patients, according to experts.
![](https://www.enttoday.org/wp-content/uploads/springboard/image/2008_05_01.gif)
Although stereotactic radiation provides a noninvasive approach to treating acoustic neuromas, it also carries the risk of hearing loss over time for a sizable portion of patients, according to experts.
Head and neck cancer care has been undergoing a paradigm shift over the past decade, moving from a surgery-based approach to one that increasingly relies on chemoradiation (CRT).
During her presentation at the 2007 Combined Otolaryngology Spring Meeting in San Diego, Dana M. Hartl, MD, PhD, from the Department of Otolaryngology Head and Neck Surgery at the Institut Gustave Roussy in France, described her findings from a retrospective, bi-institutional study designed to review the results of a large series of patients with early glottic squamous cell carcinoma treated with curative intent by transoral laser resection.
The targeted therapies erlotinib and cetuximab, in combination with standard chemotherapy regimens, are well tolerated and have very encouraging activity in recurrent/metastatic head and neck squamous cell carcinoma, according to two presentations at the American Society of Clinical Oncology (ASCO) 2007 Annual Meeting in Chicago.
Stereotactic radiotherapy is increasingly gaining favor as an attractive alternative to conventional surgery of the skull base and head and neck.
Oral screening exams are inexpensive, are easy to perform, and have the potential to reduce the annual global mortality for oral cancer by tens of thousands of people.
Part 2 of this article will discuss treatment options for skull base tumors.
Contrary to popular belief, CMS is in the business of paying for quality care, not just the volume of care provided.
According to the American Cancer Society, smokers are six times more likely than nonsmokers to develop oral cavity and oropharyngeal cancers.